Erasca Inc. Advances in Precision Oncology with FDA Clearance and Strategic Partnerships
Erasca, Inc. has made significant strategic moves, including FDA clearance of its new cancer drug ERAS-0015, and plans to seek partnerships for its phase 3 asset, positioning the company for continued growth in the precision oncology sector.
3 minutes to read